文献速递心脑血管急症重症综合管理与镇静镇痛

重症监护室快速急性镇静对比大剂量静脉抗癫痫药物治疗非惊厥性癫痫持续状态:一项随机多中心试验

Fast Acute Sedation at Intensive Care vs. High-Dose IV Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus: A Randomized, Multicenter Trial.
PubMed 文献 · Crit Care Explor · 2025-09-15
一句话结论FAST试验将首次以随机对照方式比较ICU快速深度镇静与大剂量静脉抗癫痫药物追加治疗难治性非惊厥性癫痫持续状态的疗效。

FAST试验是一项前瞻性、随机、多中心试验,计划纳入116例(预计随机约140例)对苯二氮䓬类和至少一种二线抗癫痫药物难治的非惊厥性癫痫持续状态成人患者。患者随机接受ICU内丙泊酚(必要时加用低剂量咪达唑仑)快速深度镇静20小时,或接受大剂量静脉抗癫痫药物追加治疗。主要终点为治疗失败,即随机化后24小时脑电图仍显示非惊厥性癫痫持续状态,或持续脑电图/临床评估下治疗3小时后仍持续非惊厥性癫痫持续状态。试验旨在为难治性非惊厥性癫痫持续状态提供1级证据并确立治疗标准。

要点

  • 纳入标准:成人非惊厥性癫痫持续状态,符合现行脑电图标准或具有轻微运动现象的明确非惊厥性癫痫持续状态(「轻微癫痫持续状态」),但对苯二氮䓬类和至少一种二线抗癫痫药物难治,且无持续强直-阵挛发作。
  • 干预对比:ICU内丙泊酚(必要时加用低剂量咪达唑仑)快速深度镇静20小时 vs 大剂量静脉抗癫痫药物追加治疗(左乙拉西坦、丙戊酸、磷苯妥英、拉考沙胺或托吡酯),后者在中间监护病房进行。
  • 主要终点:治疗失败,定义为随机化后24小时脑电图仍显示非惊厥性癫痫持续状态,或持续脑电图/临床评估下治疗3小时后仍持续非惊厥性癫痫持续状态。
  • 目标样本量116例,预计需随机约140例以达到所需例数;评估时间点为基线、出院及3、6、12、24个月。
  • 作者认为,无论结果如何,该试验将为难治性非惊厥性癫痫持续状态的治疗提供新的1级证据,并确立该患者群体的治疗标准。

适用人群与场景

  • 成人非惊厥性癫痫持续状态患者,符合现行脑电图标准或具有轻微运动现象的明确非惊厥性癫痫持续状态(「轻微癫痫持续状态」),但对苯二氮䓬类和至少一种二线抗癫痫药物难治,且无持续强直-阵挛发作。

诊断标准与关键阈值

  • 非惊厥性癫痫持续状态的诊断需符合现行脑电图标准,或具有轻微运动现象的明确非惊厥性癫痫持续状态(「轻微癫痫持续状态」)。
  • 难治性定义:对苯二氮䓬类和至少一种二线抗癫痫药物难治。
  • 治疗失败定义:随机化后24小时脑电图仍显示非惊厥性癫痫持续状态,或持续脑电图/临床评估下治疗3小时后仍持续非惊厥性癫痫持续状态。

处置流程与药物剂量

  • 随机分配至快速深度镇静组:在ICU内使用丙泊酚进行快速深度镇静,持续20小时,必要时加用低剂量咪达唑仑。
  • 随机分配至追加药物组:在中间监护病房接受大剂量静脉抗癫痫药物追加治疗,可选药物包括左乙拉西坦、丙戊酸、磷苯妥英、拉考沙胺或托吡酯。

研究设计与关键结果

  • FAST试验为前瞻性、随机、多中心试验方案,计划纳入116例成人难治性非惊厥性癫痫持续状态患者,预计随机约140例以达到所需例数。
  • 主要终点为治疗失败,定义为随机化后24小时脑电图仍显示非惊厥性癫痫持续状态,或持续脑电图/临床评估下治疗3小时后仍持续非惊厥性癫痫持续状态。
  • 次要终点包括新发神经功能缺损评估、出院时改良Rankin量表、经济分析、住院时长、院内感染和生存率;评估时间点为基线、出院及3、6、12、24个月。

证据类型、等级与局限

  • 证据类型:前瞻性、随机、多中心试验方案。
  • 作者认为,该试验是首个研究难治性非惊厥性癫痫持续状态的随机临床试验,无论结果如何,将提供新的1级证据并确立该患者群体的治疗标准。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该试验方案针对对苯二氮䓬类和至少一种二线抗癫痫药物难治的非惊厥性癫痫持续状态成人患者,比较ICU快速深度镇静与大剂量静脉抗癫痫药物追加治疗的疗效。
  • 作者认为,该试验结果将为难治性非惊厥性癫痫持续状态的治疗提供新的1级证据,并确立该患者群体的治疗标准。

指南或共识出处

  • FAST试验方案(Fast Acute Sedation at Intensive Care vs. High-Dose IV Anti-Seizure Medication for Treatment of Non-Convulsive Status Epilepticus),试验注册号:EU CT 2024-515507-18-00;clinicaltrials.gov NCT05263674。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The management of refractory status epilepticus (SE) remains an area of low evidence with varying management strategies. Treatment in the ICU is often postponed due to potential complications from sedation, and it is unknown if its efficacy is superior to additional treatment attempts with IV anti-seizure medications (ASMs). The Fast Acute Sedation at Intensive Care vs. High-Dose IV Anti-Seizure Medication for Treatment of Non-Convulsive Status Epilepticus (FAST) trial aims to compare the efficacy of rapid sedation in the ICU vs. add-on high-dose IV ASM alone for the treatment of refractory SE.

METHODS/RESULTS: This prospective, randomized, multicenter trial will enroll adult patients with non-convulsive status epilepticus (NCSE) who either meet current EEG criteria or have unambiguous NCSE with minor motor phenomena ("subtle SE") but without ongoing tonic-clonic seizures that are refractory to benzodiazepines and treatment with at least one second-line ASM. Patients will be randomized to receive either rapid deep sedation for 20 hours with propofol and eventually low-dose midazolam or additional high-dose IV anticonvulsant therapy (levetiracetam, valproate, fosphenytoin, lacosamide, or topiramate) in the intermediate care unit. The primary endpoint is treatment failure, either defined as NCSE on EEG 24 hours after randomization or persistent NCSE after 3 hours despite therapy on continuous EEG or clinically. Secondary endpoints include assessment of new-onset neurologic deficits and modified Rankin Scale at discharge, economic analyses, length of hospital stay, in-hospital infections, and survival. Evaluations will be performed at baseline, discharge, and 3, 6, 12, and 24 months. The target sample size is 116 patients; we expect to have to randomize about 140 patients to reach the required number of patients.

CONCLUSIONS: The FAST trial is the first randomized clinical trial to investigate refractory NCSE. Regardless of the outcome, the results of this trial protocol will provide new class 1 evidence for the treatment of NCSE and establish the standard of care for this patient population in the future.

TRIAL REGISTRATION: EU CT: 2024-515507-18-00/clinicaltrials.gov: NCT05263674.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Cornwall CD, Piilgaard H, Engedal TS, et al. Fast Acute Sedation at Intensive Care vs. High-Dose IV Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus: A Randomized, Multicenter Trial. Crit Care Explor. 2025. PMID: 40953286. doi:10.1097/CCE.0000000000001311

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。